hims compounded glp 1 🚨 SPECIAL REPORT: GLP-1s and the FDA Personalized Compounding Exemption Hims & Hers Draws Fresh

Imamura, M

Lawsuits Filed Against Novo Nordisk Plaintiffs across the United States have filed weight loss drug lawsuits against Novo Nordisk, alleging harm caused by several of its GLP-1 receptor agonist medications

Do B12 injections actually help with weight loss

We confront a formidable challenge characterized by a surging number of high-risk patients, a growing prevalence of refractory microorganisms, and a sluggish pace in the development of novel drugs

2025: Novo Nordisk announced positive Phase 3 ESSENCE trial results for semaglutide in early Alzheimer's disease, reporting statistically significant slowing of cognitive and functional decline a breakthrough data package that could establish GLP-1 therapy as a neuroprotective agent and open an addressable market of 6.5 million Alzheimer's patients in the U.S